Integragen
IntegraGen SA provides researchers with sequencing solutions, data management tools, and biostatistical, and bioinformatics support services in France. The company's genomic pharma services DNA sequencing for oncology and rare disease research; and NGS testing for cancer research. It also provides MERCURY, an online biological interpretation tool for oncology intended to assist pathologists and o… Read more
Integragen (ALINT) - Net Assets
Latest net assets as of June 2025: €338.04K EUR
Based on the latest financial reports, Integragen (ALINT) has net assets worth €338.04K EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€3.60 Million) and total liabilities (€3.26 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €338.04K |
| % of Total Assets | 9.38% |
| Annual Growth Rate | 1.07% |
| 5-Year Change | -19.15% |
| 10-Year Change | -40.13% |
| Growth Volatility | 140.29 |
Integragen - Net Assets Trend (2008–2024)
This chart illustrates how Integragen's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Integragen (2008–2024)
The table below shows the annual net assets of Integragen from 2008 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €1.76 Million | -12.68% |
| 2023-12-31 | €2.01 Million | -8.61% |
| 2022-12-31 | €2.20 Million | +0.67% |
| 2021-12-31 | €2.19 Million | +0.64% |
| 2020-12-31 | €2.17 Million | -13.43% |
| 2019-12-31 | €2.51 Million | -10.19% |
| 2018-12-31 | €2.79 Million | -28.92% |
| 2017-12-31 | €3.93 Million | +206.51% |
| 2016-12-31 | €1.28 Million | -56.28% |
| 2015-12-31 | €2.93 Million | -22.04% |
| 2014-12-31 | €3.76 Million | +443.80% |
| 2013-12-31 | €691.87K | -78.63% |
| 2012-12-31 | €3.24 Million | +4.69% |
| 2011-12-31 | €3.09 Million | -39.75% |
| 2010-12-31 | €5.13 Million | +301.04% |
| 2009-12-31 | €1.28 Million | -13.61% |
| 2008-12-31 | €1.48 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Integragen's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2220071400.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €3.36 Million | 191.66% |
| Total Equity | €1.75 Million | 100.00% |
Integragen Competitors by Market Cap
The table below lists competitors of Integragen ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
The Korea Fund Inc
F:KOF1
|
$424.38K |
|
MT Educare Limited
NSE:MTEDUCARE
|
$424.80K |
|
Rochester Resources Ltd
PINK:RCTFF
|
$424.89K |
|
PCG-P-X
PINK:PCG-P-X
|
$425.20K |
|
Cannabis Suisse Corp
PINK:CSUI
|
$424.08K |
|
Sunrise Communications AG American Depositary Shares representing Class A shares When Issued
NASDAQ:SNREV
|
$423.49K |
|
XPPT
F:XPPT
|
$423.34K |
|
ELISA (EIA.SG)
STU:EIA
|
$422.67K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Integragen's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,011,097 to 1,755,000, a change of -256,097 (-12.7%).
- Net loss of 256,000 reduced equity.
- Other comprehensive income decreased equity by 9,458.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-256.00K | -14.59% |
| Other Comprehensive Income | €-9.46K | -0.54% |
| Other Changes | €9.36K | +0.53% |
| Total Change | €- | -12.73% |
Book Value vs Market Value Analysis
This analysis compares Integragen's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.67x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.35x to 0.67x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | €0.50 | €0.18 | x |
| 2009-12-31 | €0.43 | €0.18 | x |
| 2010-12-31 | €1.36 | €0.18 | x |
| 2011-12-31 | €0.82 | €0.18 | x |
| 2012-12-31 | €0.79 | €0.18 | x |
| 2013-12-31 | €0.17 | €0.18 | x |
| 2014-12-31 | €0.76 | €0.18 | x |
| 2015-12-31 | €0.57 | €0.18 | x |
| 2016-12-31 | €0.26 | €0.18 | x |
| 2017-12-31 | €0.61 | €0.18 | x |
| 2018-12-31 | €0.43 | €0.18 | x |
| 2019-12-31 | €0.39 | €0.18 | x |
| 2020-12-31 | €0.33 | €0.18 | x |
| 2021-12-31 | €0.33 | €0.18 | x |
| 2022-12-31 | €0.33 | €0.18 | x |
| 2023-12-31 | €0.30 | €0.18 | x |
| 2024-12-31 | €0.26 | €0.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Integragen utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -14.59%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2.94%
- • Asset Turnover: 1.58x
- • Equity Multiplier: 3.14x
- Recent ROE (-14.59%) is above the historical average (-75.54%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -204.25% | -133.90% | 0.63x | 2.41x | €-3.17 Million |
| 2009 | -213.59% | -97.18% | 0.67x | 3.27x | €-2.86 Million |
| 2010 | -56.43% | -87.51% | 0.40x | 1.59x | €-3.41 Million |
| 2011 | -65.97% | -43.88% | 0.67x | 2.25x | €-2.35 Million |
| 2012 | -53.31% | -36.41% | 0.60x | 2.43x | €-2.05 Million |
| 2013 | -367.93% | -47.03% | 0.94x | 8.36x | €-2.61 Million |
| 2014 | -27.74% | -17.03% | 0.67x | 2.44x | €-1.42 Million |
| 2015 | -52.29% | -26.50% | 0.67x | 2.94x | €-1.83 Million |
| 2016 | -128.73% | -26.32% | 0.83x | 5.92x | €-1.78 Million |
| 2017 | -21.94% | -13.25% | 0.75x | 2.20x | €-1.26 Million |
| 2018 | -40.80% | -16.40% | 0.81x | 3.07x | €-1.42 Million |
| 2019 | -11.36% | -3.44% | 1.23x | 2.69x | €-535.90K |
| 2020 | -17.27% | -4.18% | 1.02x | 4.06x | €-592.22K |
| 2021 | 0.70% | 0.14% | 1.18x | 4.39x | €-203.19K |
| 2022 | -0.16% | -0.03% | 1.46x | 4.10x | €-223.56K |
| 2023 | -8.52% | -1.37% | 1.57x | 3.98x | €-372.51K |
| 2024 | -14.59% | -2.94% | 1.58x | 3.14x | €-431.50K |
Industry Comparison
This section compares Integragen's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $12,586,819
- Average return on equity (ROE) among peers: -16.06%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Integragen (ALINT) | €338.04K | -204.25% | 9.66x | $424.10K |
| Abionyx Pharma SA (ABNX) | $8.89 Million | -56.01% | 1.06x | $72.33 Million |
| Abivax SA (ABVX) | $56.72 Million | -25.23% | 0.07x | $3.97 Billion |
| Adocia (ADOC) | $-6.91 Million | 0.00% | 0.00x | $84.57 Million |
| Aelis Farma SA (AELIS) | $898.00K | 63.92% | 30.53x | $5.01 Million |
| Acticor Biotech SAS (ALACT) | $-4.04 Million | 0.00% | 0.00x | $2.13 Million |
| NicOx S.A. (ALCOX) | $21.41 Million | -97.51% | 1.47x | $28.49 Million |
| Advicenne (ALDVI) | $-1.67 Million | 0.00% | 0.00x | $15.84 Million |
| ALGAE (ALGAE) | $32.76 Million | -39.31% | 0.56x | $29.13 Million |
| Genoway (ALGEN) | $5.23 Million | 9.60% | 1.10x | $23.45K |